Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.

Vasudevan A, Woerner A, Schmeisser F, Verma S, Williams O, Weir JP.

Influenza Other Respir Viruses. 2018 Mar;12(2):250-258. doi: 10.1111/irv.12528. Epub 2017 Dec 15.

2.

A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.

Schmeisser F, Jing X, Joshi M, Vasudevan A, Soto J, Li X, Choudhary A, Baichoo N, Resnick J, Ye Z, McCormick W, Weir JP.

Influenza Other Respir Viruses. 2016 Mar;10(2):134-40. doi: 10.1111/irv.12365. Epub 2016 Jan 29.

3.

A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.

Schmeisser F, Vasudevan A, Soto J, Kumar A, Williams O, Weir JP.

Influenza Other Respir Viruses. 2014 Sep;8(5):587-95. doi: 10.1111/irv.12272. Epub 2014 Aug 2.

4.

Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.

Verma S, Soto J, Vasudevan A, Schmeisser F, Alvarado-Facundo E, Wang W, Weiss CD, Weir JP.

PLoS One. 2017 Apr 19;12(4):e0175733. doi: 10.1371/journal.pone.0175733. eCollection 2017.

5.

Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines.

Gravel C, Elmgren C, Muralidharan A, Hashem AM, Jaentschke B, Xu K, Widdison J, Arnold K, Farnsworth A, Rinfret A, Van Domselaar G, Wang J, Li C, Li X.

Vaccine. 2015 Feb 25;33(9):1129-34. doi: 10.1016/j.vaccine.2015.01.034. Epub 2015 Jan 22.

PMID:
25620245
6.

Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.

Kamal RP, Blanchfield K, Belser JA, Music N, Tzeng WP, Holiday C, Burroughs A, Sun X, Maines TR, Levine MZ, York IA.

J Virol. 2017 Sep 27;91(20). pii: e01202-17. doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.

7.

Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.

Wen Y, Palladino G, Xie Y, Ferrari A, Settembre EC.

Vaccine. 2018 May 17;36(21):3010-3017. doi: 10.1016/j.vaccine.2018.04.021. Epub 2018 Apr 19.

PMID:
29680201
8.

Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.

Li C, Xu K, Hashem A, Shao M, Liu S, Zou Y, Gao Q, Zhang Y, Yuan L, Xu M, Li X, Wang J.

Hum Vaccin Immunother. 2015;11(6):1351-6. doi: 10.1080/21645515.2015.1032490.

9.

An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.

Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP.

Vaccine. 2010 Mar 11;28(12):2442-9. doi: 10.1016/j.vaccine.2009.12.079. Epub 2010 Jan 12.

PMID:
20074687
10.

VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.

Kuck LR, Byrne-Nash R, Gillis J, Bueter K, Couzens LK, Eichelberger MC, Rowlen KL.

Vaccine. 2018 May 17;36(21):2937-2945. doi: 10.1016/j.vaccine.2018.04.048. Epub 2018 Apr 23.

11.

Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.

Vodeiko GM, Weir JP.

Influenza Other Respir Viruses. 2012 May;6(3):176-87. doi: 10.1111/j.1750-2659.2011.00285.x. Epub 2011 Sep 8.

12.

Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat.

Pierce CL, Williams TL, Santana WI, Levine M, Chen LM, Cooper HC, Solano MI, Woolfitt AR, Marasco WA, Fang H, Donis RO, Barr JR.

Vaccine. 2017 Sep 5;35(37):5011-5018. doi: 10.1016/j.vaccine.2017.07.049. Epub 2017 Jul 31.

13.

Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.

Schmeisser F, Vasudevan A, Verma S, Wang W, Alvarado E, Weiss C, Atukorale V, Meseda C, Weir JP.

PLoS One. 2015 Jan 28;10(1):e0117108. doi: 10.1371/journal.pone.0117108. eCollection 2015.

14.

A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.

Wang Y, Wu J, Xue C, Wu Z, Lin Y, Wei Y, Wei X, Qin J, Zhang Y, Wen Z, Chen L, Liu GD, Cao Y.

Antiviral Res. 2017 Jul;143:97-105. doi: 10.1016/j.antiviral.2017.03.029. Epub 2017 Apr 10.

PMID:
28408133
15.

An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Krammer F, Jul-Larsen A, Margine I, Hirsh A, Sjursen H, Zambon M, Cox RJ.

Clin Vaccine Immunol. 2014 Aug;21(8):1153-63. doi: 10.1128/CVI.00272-14. Epub 2014 Jun 18.

16.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

17.

Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.

Zhang L, Jia N, Li J, Han Y, Cao W, Wang S, Huang Z, Lu S.

Hum Vaccin Immunother. 2014;10(7):1949-58. doi: 10.4161/hv.28795.

18.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811
19.

Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines.

Legastelois I, Chevalier M, Bernard MC, de Montfort A, Fouque M, Pilloud A, Serraille C, Devard N, Engel O, Sodoyer R, Moste C.

J Virol Methods. 2011 Dec;178(1-2):129-36. doi: 10.1016/j.jviromet.2011.08.027. Epub 2011 Aug 31.

PMID:
21907241
20.

Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination.

Morgenstern K, Xie Y, Palladino G, Barr JR, Settembre EC, Williams TL, Wen Y.

Vaccine. 2018 Oct 1;36(41):6144-6151. doi: 10.1016/j.vaccine.2018.08.065. Epub 2018 Sep 5.

PMID:
30194004

Supplemental Content

Support Center